Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary

Key facts

Sponsor

National Cancer Institute (NCI)

Principal Investigator

Jubilee Brown, MD

NRG Oncology

Intervention

Bevacizumab(biological)

Enrollment

36 enrolled

Eligibility

18 years · FEMALE

Timeline

2008 – 2013

Study locations (30)

• Los Angeles County-USC Medical Center, Los Angeles, California, United States
• USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
• University of Colorado Hospital, Aurora, Colorado, United States
• Hartford Hospital, Hartford, Connecticut, United States
• The Hospital of Central Connecticut, New Britain, Connecticut, United States
• Northeast Georgia Medical Center-Gainesville, Gainesville, Georgia, United States
• Northwestern University, Chicago, Illinois, United States
• University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
• Hinsdale Hematology Oncology Associates Incorporated, Hinsdale, Illinois, United States
• Sudarshan K Sharma MD Limted-Gynecologic Oncology, Hinsdale, Illinois, United States
• University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
• Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
• University of Massachusetts Memorial Health Care, Worcester, Massachusetts, United States
• University of Massachusetts Medical School, Worcester, Massachusetts, United States
• University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

NRG Oncology

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.